HomeCompareETIVF vs JNJ

ETIVF vs JNJ: Dividend Comparison 2026

ETIVF yields 7535.80% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ETIVF wins by $4255.74M in total portfolio value
10 years
ETIVF
ETIVF
● Live price
7535.80%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4255.77M
Annual income
$153,468,497.41
Full ETIVF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — ETIVF vs JNJ

📍 ETIVF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodETIVFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ETIVF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ETIVF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ETIVF
Annual income on $10K today (after 15% tax)
$640,542.58/yr
After 10yr DRIP, annual income (after tax)
$130,448,222.80/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, ETIVF beats the other by $130,444,236.81/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ETIVF + JNJ for your $10,000?

ETIVF: 50%JNJ: 50%
100% JNJ50/50100% ETIVF
Portfolio after 10yr
$2127.90M
Annual income
$76,736,593.41/yr
Blended yield
3.61%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ETIVF
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ETIVF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricETIVFJNJ
Forward yield7535.80%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%28%
Portfolio after 10y$4255.77M$30.3K
Annual income after 10y$153,468,497.41$4,689.40
Total dividends collected$3348.41M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ETIVF vs JNJ ($10,000, DRIP)

YearETIVF PortfolioETIVF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$387,490$376,789.75$10,592$272.30+$376.9KETIVF
2$7,237,145$6,822,531.17$11,289$357.73+$7.23METIVF
3$67,287,857$59,544,111.75$12,123$472.89+$67.28METIVF
4$330,696,834$258,698,826.79$13,141$629.86+$330.68METIVF
5$947,965,411$594,119,798.48$14,408$846.81+$947.95METIVF
6$1,810,157,386$795,834,396.79$16,021$1,151.60+$1810.14METIVF
7$2,646,990,094$710,121,690.29$18,122$1,588.22+$2646.97METIVF
8$3,317,517,601$485,238,201.06$20,930$2,228.20+$3317.50METIVF
9$3,833,929,474$284,185,640.85$24,792$3,191.91+$3833.90METIVF
10$4,255,773,035$153,468,497.41$30,274$4,689.40+$4255.74METIVF

ETIVF vs JNJ: Complete Analysis 2026

ETIVFStock

Unbound Group plc, formerly known as Electra Private Equity PLC, specializes in growth capital, buyouts, recapitalization, control buyouts, PIPEs, middle market investments. It invests across all sectors and is not sector specific. The fund seeks to invest in companies based in the Continental Europe, United States and principally in Western Europe, with the majority of investments made in the United Kingdom. It typically invests between £40 million ($49.79 million) and £150 million ($180.73 million). It also co-invests £30 million ($37.35 million) to £100 million ($124.49 million) in minority positions in UK or International companies, alongside founders, other private equity firms, corporates or the public markets. It makes both minority and majority investments. The fund structures its investments through equity, senior equity, and convertible and mezzanine debt. It invests directly from its balance sheet.

Full ETIVF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this ETIVF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ETIVF vs SCHDETIVF vs JEPIETIVF vs OETIVF vs KOETIVF vs MAINETIVF vs ABBVETIVF vs MRKETIVF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.